PepGen's exhibits slightly volatile volatility while gaining momentum overall. Forward projections suggest a move toward approximately -59.1 M. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
PepGen Correlation provides competitor comparison context for PepGen. The view adds relative comparison context.
Learn how to buy and trade PepGen Stock using our step-by-step How to Buy PepGen guide.
The Net Income Applicable To Common Shares trend for PepGen offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether PepGen is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest PepGen's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of PepGen over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. PepGen's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PepGen's overall financial position and show how it may be relating to other accounts over time.
PepGen Net Income Applicable To Common Shares Regression Statistics
Arithmetic Mean
-21,965,148
Coefficient Of Variation
-135.92
Mean Deviation
26,362,309
Median
-1,346,000
Standard Deviation
29,855,990
Sample Variance
891.4T
Range
67.8M
R-Value
-0.82
Mean Square Error
305.4T
R-Squared
0.68
Significance
0.000048
Slope
-4,871,259
Total Sum of Squares
14262.1T
PepGen Net Income Applicable To Common Shares History
2026
-59.1 M
2025
-62.2 M
2022
-69.1 M
2021
-27.3 M
2020
-4.1 M
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Pepgen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people. A high-level view of PepGen emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 2.61. PepGen has market cap of 425.75 M, ROE of -67.39%.
Methodology
Unless otherwise specified, financial data for PepGen is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. PepGen (USA Stocks:PEPG) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for PepGen incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
PepGen is covered by 7 analysts. 3 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include J.P. Morgan, Stifel, BMO Capital Markets, Oppenheimer & Co., Citigroup, RBC Capital Markets, among others. Updates may occur throughout the day.
Reviewing PepGen commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for PepGen Stock. Below are reports that help frame PepGen Stock in context:
PepGen Correlation provides competitor comparison context for PepGen. The view adds relative comparison context.
Learn how to buy and trade PepGen Stock using our step-by-step How to Buy PepGen guide.Analysis related to PepGen should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Earnings Share
-2.12
Return On Assets
-0.36
Return On Equity
-0.67
Understanding PepGen includes distinguishing between market value and book value, where book value reflects PepGen accounting equity. PepGen's market capitalization is 425.75 M. A P/B ratio of 2.61 indicates the market values PepGen above its accounting book value. Enterprise value stands at 253.52 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for PepGen differs from its quoted price, since each reflects a different lens. For PepGen, key inputs include a P/B ratio of 2.61, and ROE of -67.39%. By contrast, market price reflects the level where buyers and sellers transact.